A detailed history of First Horizon Advisors, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 688 shares of BCRX stock, worth $4,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares
688
Previous 688 -0.0%
Holding current value
$4,410
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $2,723 - $4,061
343 Added 99.42%
688 $5,000
Q3 2022

Nov 09, 2022

BUY
$10.79 - $14.81 $3,722 - $5,109
345 New
345 $4,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.19B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.